Introduction
============

Prostate diseases in general and prostate cancer (PC) in particular are major concerns of public health care. One eighth to one sixth of males will develop PC and experience the risk of prostate cancer progression if not properly diagnosed, monitored and treated. Molecular markers for diagnosis and disease progression risk assessment are extremely necessary. One of the palliative treatments for advanced prostate cancer is androgen blockade, achieved by chemical or surgical castration. Besides the psychological and physiological side effects, the risk of androgen blockade resides in the common progression to the highly malignant and life-threatening form of castration-resistant prostate cancer (CRPC). Several mutations and chromosomal rearrangements have been associated with PC and CRPC. Recently, a series of chromosomal translocations including frequent bridging and rearrangements was described and demonstrated to occur in a few steps and to affect a series of important tumor suppressors ([@B6]). Nonetheless, the linear progression among progressive stages has been questioned, as metastatic lesions are clonally derived, show signatures particular to each affected individual and might result from less advanced local primary lesions ([@B15], [@B13]).

Androgens, acting through the androgen receptor (AR), are required for prostate development and normal function ([@B33]). Hence, surgical or chemical castration defines a hypoandrogenic state in which a series of events sum up to promote organ (and tumor) shrinkage; androgen deprivation/blocking is the first line therapy for advanced prostate cancer. Gain-of-function mutations enabling the AR to recover activity in the hypoandrogen environment have been associated with the progression to CRPC ([@B12]), and include mutations, deletions and inversions at the ligand binding site leading to ligand-independent activation ([@B28]), and gene amplifications. In spite of these AR-centered modifications, a series of genes has been implicated in prostate cancer progression, including overall changes in gene expression ([@B1], [@B39], [@B34]) and complex chromosomal rearrangements frequently involving *PTEN*, *NKX3.1*, *SPOP, CHD1, TP53, MAP3K7, FOXP1* and the *T2-ERG* fusion ([@B6]).

Furthermore, we consider that other physiological aspects of the adaptation to the hypoandrogen environment might be corrupted in cancer cells, and cooperate in establishing the selective pressure that contributes to the clonality of cells harboring chromosomal changes in general and AR modifications in particular.

Although epithelial cell apoptosis is a major event in prostate regression occurring in response to castration, it is not the sole event. For instance, remarkable reprogramming of immune system cells ([@B10]) and smooth muscle cells ([@B4], [@B3]) as well as reorganization of the extracellular matrix ([@B40]) have been described and associated with a re-defined functional state and immune barrier system. Additionally, we have reported the occurrence of desquamation as an additional phenomenon contributing to epithelial cell deletion ([@B31]), and a relevant role for two macrophage subpopulations in both (a) the induction of epithelial cell death ([@B7]) and (b) the clearance of cell corpses and maintenance of the non-inflammatory status ([@B35]).

However, little has been studied beyond the induction of apoptosis in epithelial cells. Progress has been made in terms of showing that epithelial expression of the AR is not necessary for epithelial cell death ([@B21]), while the remaining cells develop resistance to androgen deprivation and preserve a differentiation-immature signature ([@B32]).

The rat ventral prostate has been a valuable and robust *in vivo* model system to explore androgen regulation of gene expression ([@B41], [@B22], [@B10]). The ventral prostate responds to androgen withdrawal with increased epithelial cell apoptosis, whereas the dorsolateral lobes show negligible cell death ([@B22]). The responsiveness of the ventral prostate to androgens is also characterized by the number of differentially expressed genes after castration as compared to the dorsolateral lobe (1496 vs. 256 genes, respectively) ([@B10]). Most of these changes take place in the hypoandrogen environment, and are triggered by disengaging AR signaling.

We hypothesized that other transcription factors (TF) and transcriptional regulators (TR) are co-opted to coordinate the sequential changes observed in the gland after castration. In this work, we explore this idea in an attempt to find new genes, unforeseen metabolic process and chromosomal hotspots that might reveal possible connections between gland physiology under androgen deprivation promoted by castration and progression to CRPC after hormone therapies.

We have used bioinformatics to (a) select class-specific genes from a published list of genes and ESTs differentially expressed in response to castration and androgen supplementation after DNA microarray analysis, (b) to identify the regulatory networks in which the selected genes are involved, (c) to map the homologs of rat genes to human chromosomes, and (d) to find mutations and/or copy number alterations and changes in patient survival.

Accordingly, this study has unveiled a list of TF and TR genes and a series of unexplored physiological pathways, such as circadian rhythms (genes Arnt/Bhlhe41/Dpb) and peroxisome biogenesis (Pex14), hitherto neglected pathways in prostate biology. We also correlated the selected genes with chromosomal regions commonly deleted in prostate cancer, such as 10q23, which contains the *PTEN*/*HHEX*/*MXI1* gene cluster, and 22q11.21, harboring the MAPK1 gene, found 20 genes mutated in at least 5% of three patient cohorts and six genes affecting patient survival when mutated.

Materials and Methods
=====================

The microarray data from [@B10] reported 1496 genes/ESTs differentially expressed in response to castration and testosterone supplementation. The list of gene bank accession IDs for all genes and ESTs was loaded into DAVID v6.7. Gene IDs and biological annotations are highly redundant within the vast array of public databases. The DAVID knowledge base collects and integrates various gene identifiers as well as more than 40 well-known publicly annotation categories, which are then centralized by the internal DAVID identifier in a non-redundant manner. A significant portion of input gene IDs failed to be mapped and were then processed using the gene ID conversion tool. All the identified IDs/gene names were listed by the gene name batch viewer. We further processed the identified IDs for the identification of functional annotations centered on TFs and TRs, and the identified genes were further studied to find their functional annotation clustering and possible integration in known biological functions.

The TFs/TRs were also studied for possible functional associations using the Ingenuity Pathway Analysis (IPA) software, with filtering for information in the rat, and choosing only direct interactions.

The human homologs to the rat genes were searched manually using the NCBI database, and their chromosomal location was used to map them to the human ideogram.

Finally, we assessed the cBioPortal (cbioportal.org) and checked three cohorts of prostate adenocarcinomas for the existence of mutations and/or copy number alterations and possible effect on patient survival ([@B5], [@B23], [@B2]).

A limit of 5% mutations and a log rank test p-value smaller than 0.05% were set for each analysis, respectively.

Results
=======

Data processing
---------------

Using the gene accession conversion tool of DAVID v6.7, the program managed to convert 468 IDs from the list of 1477 total unique user IDs. The number of genes identified was similar to that obtained in the original work ([@B10]). Out of the 468 IDs, DAVID identified 60 TFs/TRs. Table 1 lists the detailed annotation and functional enrichment information that was retrieved using the terms TFs/TRs. The chromosomal location for each gene was determined using the NCBI databank. Twenty-two genes were identified as transcription factors (bold in Table 1).

###### Genes with accession numbers, names and functions and chromosomal location in the rat chromosomes as well as the chromosomal location of the human homologs. Known and putative transcription factors are bold-faced.

  S.No   Gene Accession Number   Gene Name                                                                                                                                                    Abbreviation   Rat Chromosome location   Location of the human homolog   Gene Function
  ------ ----------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------ -------------- ------------------------- ------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  1      NM_017259               B-cell translocation gene 2, anti-proliferative                                                                                                              Btg2           13q13-q31                 1q32                            Regulation of transcription
  2      NM_057109               BarH-like homeobox 1                                                                                                                                         **Barhl1**     3p12                      9q34                            Regulation of transcription, transcription factor activity
  3      NM_013154               CCAAT/enhancer binding protein (C/EBP), delta                                                                                                                **Cebpd**      11                        8p11.2-p11.1                    Regulation of transcription from RNA polymerase II promoter, transcription factor activity
  4      NM_012543               D site of albumin promoter (albumin D-box) binding protein                                                                                                   **Dbp**        1q22                      19q13.3                         Transcription factor activity, Basic-leucine zipper (bZIP) transcription factor
  5      NM_020083               GTPase activating Rap/RanGAP domain-like 1                                                                                                                   Ralgapa1       6q23                      14q13.2                         Regulation of transcription
  6      NM_012855               Janus kinase 3                                                                                                                                               Jak3           16p14                     19p13.1                         Regulation of transcription, transcription factor binding
  7      NM_013160               MAX interactor 1                                                                                                                                             Mxi1           1q55                      10                              DNA binding, transcription repressor activity, transcription regulator activity
  8      NM_022856               Ngfi-A binding protein 1                                                                                                                                     Nab1           9q22                      2q32.3-q33                      Transcription repressor activity, transcription regulator activity
  9      NM_019275               SMAD family member 4                                                                                                                                         **Smad4**      18q12.3                   18q21.1                         Transcription factor complex, transcription activator activity, transcription regulator activity
  10     NM_017359               RAB10, member RAS oncogene family                                                                                                                            Rab10          6q12                      2p23.3                          Regulation of transcription, transcription factor binding
  11     NM_021693               SNF1-like kinase                                                                                                                                             Sik1           20p12                     21q22.3                         Transcription repressor activity, transcription regulator activity
  12     NM_012903               Acidic (leucine-rich) nuclear phosphoprotein 32 family, member A                                                                                             Anp32a         8q24                      15q23                           Regulation of transcription
  13     NM_031018               Activating transcription factor 2                                                                                                                            **Atf2**       3q23                      2q32                            Transcription factor activity, transcription activator, Basic-leucine zipper (bZIP) transcription factor, Cyclic AMP-dependent transcription factor ATF-2, bZIP transcription factor
  14     M64780                  Agrin                                                                                                                                                        Agrn           5q36                      1p36.33                         Regulation of transcription, regulation of transcription from RNA polymerase II promoter
  15     NM_012907               Apolipoprotein B mRNA editing enzyme, catalytic polypeptide 1                                                                                                Apobec1        4q42                      12p13.1                         Posttranscriptional regulation of gene expression
  16     AF015953                Aryl hydrocarbon receptor nuclear translocator-like                                                                                                          **Arntl**      1q34                      11p15                           Positive regulation of transcription, transcription factor activity
  17     AF009329                Basic helix-loop-helix family, member e41                                                                                                                    **Bhlhe41**    4q43                      12p12.1                         Transcription regulator activity
  18     NM_017338               Calcitonin/calcitonin-related polypeptide, alpha                                                                                                             Calca          1q34                      11p15.2                         Regulation of transcription
  19     X83579                  Cyclin-dependent kinase 7                                                                                                                                    Cdk7           2q12                      5q12.1                          Transcription factor complex, transcription regulation
  20     NM_012698               Dystrophin, muscular dystrophy                                                                                                                               Dmd            Xq22                      Xp21.2                          Regulation of transcription
  21     NM_012754               Estrogen receptor 2 (ER beta)                                                                                                                                **Esr2**       6q24                      14q23.2                         Transcription factor activity
  22     NM_031041               General transcription factor IIB                                                                                                                             **Gtf2b**      2q44                      1p22-p21                        transcription initiation, transcription factor complex, Transcription factor TFIIB related
  23     J05181                  Glutamate-cysteine ligase, catalytic subunit                                                                                                                 Gclc           8q31                      6p12                            Regulation of transcription
  24     NM_021592               Heart and neural crest derivatives expressed 1                                                                                                               **Hand1**      10q22                     5q33                            DNA binding, transcription factor activity, transcription cofactor activity, transcription coactivator activity, transcription factor binding, enzyme binding, transcription regulator activity, bHLH transcription factor binding
  25     NM_024385               Hematopoietically expressed homeobox                                                                                                                         **Hhex**       1q53                      10q23.33                        DNA binding, transcription factor activity, eukaryotic initiation factor 4E binding, general transcriptional repressor activity, transcription regulator activity, translation initiation factor binding, sequence-specific DNA binding,
  26     NM_032070               High mobility group AT-hook 2                                                                                                                                Hmga2          7q22                      12q15                           Regulation of transcription
  27     NM_031787               Homeodomain interacting protein kinase 3                                                                                                                     Hipk3          3q32                      11p13                           Regulation of transcription
  28     NM_019356               Eukaryotic Translation initiation factor 2, subunit 1 alpha                                                                                                  Eif2s1         6q24                      14q23.3                         Posttranscriptional regulation of gene expression
  29     NM_013060               Inhibitor of DNA binding 2                                                                                                                                   **Id2**        6q16                      2p25                            Regulation of transcription factor activity,
  30     NM_053355               Inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta                                                                                   Ikbkb          16q12.5                   8p11.2                          Regulation of transcription factor activity, positive regulation of NF-kappaB transcription factor activity
  31     NM_012591               Interferon regulatory factor 1                                                                                                                               Irf1           10q22                     5q31.1                          DNA binding, transcription factor activity, sequence-specific DNA binding
  32     NM_053842               Mitogen activated protein kinase 1                                                                                                                           Mapk1          11q23                     22q11.21                        Transcription factor binding, positive regulation of transcription
  33     NM_017322               Mitogen-activated protein kinase 9                                                                                                                           Mapk9          10q22                     5q35                            Regulation of transcription
  34     NM_053718               myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila); translocated to, 3                                                               Mllt3          5q32                      9p22                            Regulation of transcription
  35     U68726                  Neogenin homolog 1 (chicken)                                                                                                                                 Neo1           8q24                      15q22.3-q23                     Transcription regulator activity
  36     NM_012866               Nuclear transcription factor-Y gamma                                                                                                                         **Nfyc**       5q36                      1p32                            DNA binding, transcription factor activity, sequence-specific DNA binding,
  37     NM_053869               Paired-like homeobox 2a                                                                                                                                      **Phox2a**     1q32                      11q13.2                         DNA binding, transcription factor activity, sequence-specific DNA binding
  38     AB017544                Peroxisomal biogenesis factor 14                                                                                                                             Pex14          5q36                      1p36.22                         Transcription cofactor activity, transcription corepressor activity, transcription factor binding, transcription repressor activity,
  39     NM_031606               Phosphatase and tensin homolog                                                                                                                               Pten           1q41-q43                  10q23.3                         Posttranscriptional regulation of gene expression,
  40     NM_013063               poly (ADP-ribose) polymerase 1                                                                                                                               Parp1          13q26                     1q41-q42                        Transcription regulation
  41     NM_053949               potassium voltage-gated channel, subfamily H (eag-related), member 2                                                                                         Kcnh2          4q11                      7q36.1                          Transcription regulation
  42     NM_019243               prostaglandin F2 receptor negative regulator                                                                                                                 Ptgfrn         2q34                      1p13.1                          Posttranscriptional regulation of gene expression
  43     NM_031149               proteasome (prosome, macropain) 26S subunit, ATPase, 5                                                                                                       Psmc5          10q32.1                   17q23.3                         Regulation of transcription, transcription factor binding
  44     NM_031528               Retinoic acid receptor, alpha                                                                                                                                **Rara**       10q31                     17q21                           Transcription factor activity, transcription cofactor activity, transcription coactivator activity, Transcription, transcription
  45     AJ223083                Retinoid X receptor gamma                                                                                                                                    **Rxrg**       13q24                     1q22-q23                        Transcription factor activity, transcription regulator activity
  46     L29259                  Similar to transcription elongation factor B (SIII), polypeptide 1; transcription elongation factor B (SIII), polypeptide 1                                  Tceb1          5q11                      8q21.11                         RNA polymerase II transcription factor activity, transcription elongation regulator activity, regulation of transcription
  47     NM_030835               Stress-associated endoplasmic reticulum protein 1                                                                                                            Serp1          2q31                      3q25.1                          Posttranscriptional regulation of gene expression,
  48     L08814                  Structure specific recognition protein 1                                                                                                                     Ssrp1          3q24                      11q12                           DNA binding, transcription regulator activity
  49     NM_053800               Thioredoxin 1                                                                                                                                                Txn1           5q24                      9q31                            Regulation of transcription
  50     U30789                  Thioredoxin interacting protein                                                                                                                              Txnip          2q34                      1q21.1                          Regulation of transcription
  51     NM_012887               Thymopoietin                                                                                                                                                 Tmpo           7q13                      12q22                           Regulation of transcription
  52     J03819                  Thyroid hormone receptor beta                                                                                                                                **Thrb**       15p16                     3p24.2                          DNA binding, double-stranded DNA binding, transcription factor activity
  53     U54632                  Transmembrane protein 215; similar to Ubiquitin-conjugating enzyme E2 I (Ubiquitin-protein ligase I) (Ubiquitin carrier protein I) (SUMO-1-protein ligase)   Ube2i          10q12                     16p13.3                         transcription factor binding, specific transcriptional repressor activity, transcription regulator activity, bHLH transcription factor binding
  54     NM_013091               Tumor necrosis factor receptor superfamily, member 1a                                                                                                        Tnfrsf1a       4q42                      12p13.2                         Regulation of transcription
  55     NM_053928               Ubiquitin-conjugating enzyme E2N; similar to ubiquitin-conjugating enzyme E2N (homologous to yeast UBC13)                                                    Ube2n          7q13                      Xq27                            Regulation of transcription factor activity, regulation of transcription
  56     NM_012555               v-ets erythroblastosis virus E26 oncogene homolog 1 (avian)                                                                                                  **Ets1**       8q21                      11q23.3                         Transcription factor activity, transcription regulator activity, sequence-specific DNA binding
  57     NM_017058               Vitamin D (1, 25- dihydroxyvitamin D3) receptor                                                                                                              **Vdr**        7q36                      12q13.11                        DNA binding, transcription factor activity, transcription factor binding
  58     X52590                  Zinc finger protein 36, C3H type-like 1                                                                                                                      **Zfp36l1**    6q24                      14q22-q24                       Posttranscriptional regulation of gene expression
  59     AF072439                Zinc finger protein 37                                                                                                                                       **Zfp37**      5q24                      9q32                            Regulation of transcription
  60     AF052042                Zinc finger protein 394                                                                                                                                      **Zfp394**     12p11                     7q22.1                          Transcription factor activity, Regulation of transcription

Roles of transcription factors and functional associations among the selected genes
-----------------------------------------------------------------------------------

The selected TFs and TRs function in 17 important cellular pathways identified by DAVID (Table 2). Some of the ontogenies were very general (such as "Pathways in cancer" or "Prostate cancer" or "Type II diabetes mellitus"); all but 3 (14/17) included *Mapk1*, and about half (9/17) contained *Mapk9*, related to areas of strong research or hubs in central signaling pathways. The ontogenies also pointed to TGF-β, Toll-like receptors and T-cell receptor signaling pathways. Novel ontogenies implicated the genes *Arnt* and *Bhlhe41* in "Circadian rhythms" and *Ets-1* (E26 oncogene homolog 1) in "Dorso-ventral axis formation".

###### Regulatory pathways involving the selected genes identified by DAVID.

  S.No   Pathway                                Gene name                                                                                                                                                                                                                                         Genes count   \%     P-Value   Benjamini's false discovery rate
  ------ -------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------- ------ --------- ----------------------------------
  1      Pathways in cancer                     SMAD family member 4 B-cells, kinase beta Mitogen activated protein kinase 1 Mitogen-activated protein kinase 9 Phosphatase and tensin homolog Retinoic acid receptor, alpha Retinoid X receptor gamma transcription elongation factor B (SIII)   8             13.3   4.5E-4    3.3E-2
  2      Adipocytokine signaling pathway        B-cells, kinase beta Mitogen-activated protein kinase 9 Retinoid X receptor gamma Superfamily, member 1a                                                                                                                                          4             6.7    3.5E-3    1.2E-1
  3      Pancreatic cancer                      SMAD family member 4 B-cells, kinase beta Mitogen activated protein kinase 1 Mitogen-activated protein kinase 9                                                                                                                                   4             6.7    3.8E-3    8.9E-2
  4      Type II diabetes mellitus              B-cells, kinase beta Mitogen activated protein kinase 1 Mitogen-activated protein kinase 9                                                                                                                                                        3             5.0    2.1E-2    3.3E-1
  5      Acute myeloid leukemia                 B-cells, kinase beta Mitogen activated protein kinase 1 Retinoic acid receptor, alpha                                                                                                                                                             3             5.0    2.7E-2    3.3E-1
  6      MAPK signaling pathway                 Activating transcription factor 2 B-cells, kinase beta Mitogen activated protein kinase 1 Mitogen-activated protein kinase 9 Superfamily, member 1a                                                                                               5             8.3    3.3E-2    3.3E-1
  7      NOD-like receptor signaling pathway    B-cells, kinase beta Mitogen activated protein kinase 1 Mitogen-activated protein kinase 9                                                                                                                                                        3             5.0    3.3E-2    3.0E-1
  8      Renal cell carcinoma                   Mitogen activated protein kinase 1 Transcription elongation factor B (SIII) E26 oncogene homolog 1 (avian)                                                                                                                                        3             5.0    4.0E-2    3.1E-1
  9      Chronic myeloid leukemia               SMAD family member 4 B-cells, kinase beta Mitogen activated protein kinase 1                                                                                                                                                                      3             5.0    4.7E-2    3.2E-1
  10     Colorectal cancer                      SMAD family member 4 Mitogen activated protein kinase 1 Mitogen-activated protein kinase 9                                                                                                                                                        3             5.0    5.4E-2    3.3E-1
  11     Small cell lung cancer                 B-cells, kinase beta Phosphatase and tensin homolog Retinoid X receptor gamma                                                                                                                                                                     3             5.0    5.6E-2    3.2E-1
  12     Circadian rhythm                       Aryl hydrocarbon receptor Basic helix-loop-helix family, member e41                                                                                                                                                                               2             3.3    5.9E-2    3.1E-1
  13     TGF-beta signaling pathway             SMAD family member 4 Inhibitor of DNA binding 2 Mitogen activated protein kinase 1                                                                                                                                                                3             5.0    6.0E-2    2.9E-1
  14     Prostate cancer                        B-cells, kinase beta Mitogen activated protein kinase 1 Phosphatase and tensin homolog                                                                                                                                                            3             5.0    6.5E-2    3.0E-1
  15     Toll-like receptor signaling pathway   B-cells, kinase beta Mitogen activated protein kinase 1 Mitogen-activated protein kinase 9                                                                                                                                                        3             5.0    6.5E-2    3.0E-1
  16     T cell receptor signaling pathway      B-cells, kinase beta Mitogen activated protein kinase 1 Mitogen-activated protein kinase 9                                                                                                                                                        3             5.0    9.0E-2    3.7E-1
  17     Dorso-ventral axis formation           Mitogen activated protein kinase 1 E26 Oncogene homolog 1 (avian)                                                                                                                                                                                 2             3.3    9.8E-2    3.7E-1

Upon further inspection, using IPA to set the interactions among the 60 genes, we found eight networks corresponding to known pathways ([Figure 1](#f1){ref-type="fig"}; Table S1). They vary in terms of the number of individual nodes, but reveal interesting aspects of the yet-to-be proven physiology of the prostate gland in the hypoandrogen environment. Perhaps not surprisingly, they are ascribed to gene expression regulation, cell death and survival, and also to nucleic acid and carbohydrate metabolism and cancer. They also implicate particular pathways such as estrogen receptor, retinoic acid receptor, thyroid hormone receptor, NFκB signaling, TGF-β and establishing connections with the newly identified genes. It is interesting to note that *Arntl* and *Bhlhe41*, both involved in circadian rhythms (Pathway 12, in [Table 2](#t2){ref-type="table"}), appeared together in network number 2 ([Figure 1](#f1){ref-type="fig"}). *Arntl* connected to the AR via either p300/EP300 or CREBBP acetyl transferases, and directly do *Dbp*, another circadian rhythm gene. Additionally, IPA retrieved one particularly interesting pathway, peroxisomal biogenesis and function, referenced by network number 8, which is centered on the gene *Pex14*.

![Functional associations among the 60 TF/TR in eight networks, according to IPA. Functional descriptors are presented in Table S1. The genes shown in gray are those identified in this work.](1415-4757-GMB-42-4-e20180362-gf01){#f1}

Chromosomal mapping
-------------------

We identified the human homolog for each gene ([Table 1](#t1){ref-type="table"}) and determined their location in the human chromosomes ideogram, also using the NCBI databank. This data set was used to localize each gene in the human ideogram ([Figure 2](#f2){ref-type="fig"}). Chromosome 1 contained eight genes (*AGRN*, *PEX14*, *NFYC*, *GTF2B*, *PTGFRN*, *TXNIP*, *RXRG*, *BTG2*, *PARP1*) and small clusters were observed in 2q (*SERP1*, *ATF2*, *NAB1*), 5q (*IRF1*, *HAND1*, *MAPK9*), 9q (*TXN1*, *ZPF37*, *BARHL1*), 10q (*PTEN*, *HHEX*, *MXI1*), 12p (*TNFRSF1A*, *APOBEC1*, *BHLHE41*) and 14q (*ZFP36L1*, *ESR2*, *EIF2S1*). The 10q23 region included *Pten*, *Hhex* and *Mxi1*. In contrast, not a single gene among the selected 60 mapped to chromosomes 4, 13, 16, 20 and Y. Areas of frequent variation (i.e. gains or deletions) ([@B18]) were included for the determination of proximity to the set of the human homologs of the selected genes. The location of the regions frequently affected by gains/losses in healthy individuals ([@B18]) revealed almost no association with the selected genes ([Figure 2](#f2){ref-type="fig"}). On the other hand, half of the selected genes were mapped to chromosomal regions found to be amplified or deleted in prostatic diseases ([Figure 3](#f3){ref-type="fig"}). Associations were found with metastatic cancer (12/6; gains/losses), localized high (1/4; gain/losses) and low risk (1 loss; *RXRG*), prostate intraepithelial neoplasia (PIN) (2/1; gains/loss) ([@B20]), and with the intermediate risk prostate cancer (6 losses) ([@B19]). Remarkably, ETS1 and IRF1 appeared in regions of gains in PIN but not in other disease states, and MAPK1 and SIK1 were located in (or nearby) regions deleted in intermediate-risk cancer.

![Mapping of the human orthologs of 60 TF/TR rat genes to the human ideogram. Indicated are the regions of copy number gain (blue) and losses (red) reported for healthy human individuals, according to [@B18].](1415-4757-GMB-42-4-e20180362-gf02){#f2}

![Association of frequently amplified (red), deleted (green) or both (hatched) chromosomal regions harboring 30 of the selected TF/TR in metastatic prostate cancer (MET), prostate cancer (PCA), high grade PCA (H-PCA), low grade PCA (L-PCA), prostate intraepithelial neoplasia (PIN), and intermediate risk PCA (I-PCA). Based on [@B20] and [@B19].](1415-4757-GMB-42-4-e20180362-gf03){#f3}

Mutation rates and effect on patient survival
---------------------------------------------

PTEN is a tumor suppressor frequently associated with prostate cancer ([@B1], [@B39], [@B34], [@B6]). We found PTEN mutated in 16%, 21% and 33% of the patients for the three cohorts studied. Beside PTEN, only IKBKB was found mutated in at least 5% of the patients in the three cohorts. CEBPD and DMD showed mutations in more than 10% of the patients in one cohort. BTG2, SERP1, CKNH2, RXRG, TXN1P, UBE2I, ZFP37, BARHL1, RALGAPA1, CDK7, PARP1, PTEFGRN, TXN1, TMPO, TNFRSF1A and AGRN were mutated in at least 5% of the patients in at least one cohort. However, more than 50% of the studied genes showed deletions in the three cohorts.

Survival curves existed for two of the three cohorts studied. PHOX2a and NFYC were associated with significant impact on patient survival (P \< 0.05) in the first cohort and EST2, EIF251, SSRP1 and PARP1, in the second cohort.

Discussion
==========

Sixty differentially expressed TF and TR were retrieved from the microarray data published by Desai *et al.* ([@B10]). These genes were assorted into 17 pathways by the DAVID knowledge base and into eight functional networks by Ingenuity Pathway Analysis (IPA). Though most these pathways were too general, and led to central metabolic hubs, such as PTEN (which was further validated in the parent study) and nuclear receptors pathways, some revealed particularly interesting and unforeseen aspects of prostate biology, such as circadian rhythms and peroxisome biogenesis. The selected genes were also mapped to chromosome regions frequently affected in prostate cancers, as their identification might serve as risk factors or therapeutic targets relevant to progression to CRPC. Additionally, 20 genes were found mutated in at least 5% of prostate adenocarcinoma patients.

We used the DAVID module Gene ID Conversion Tool ([@B16], [@B17]) to identify gene IDs from the initial gene list. The number of genes was roughly the same as those uncovered in the parent study, perhaps indicating a potential limit for retrieving information from the early commercially available microarray chips. In order to further advance our understanding of the physiology and endocrinology of the VP gland and to facilitate the biological interpretation of prostate biology in a broad range of biological processes, the 468 genes were further processed to track down their functional classification and resulted in 60 different TF or TR, which were then assigned to known regulatory pathways using DAVID and to functional interaction networks using IPA, resulting in the identification of 22 transcription factors.

Prostate cancer will affect one eighth to one sixth of men worldwide. In spite of enormous progress in the understanding of many facets of the disease, new concepts are still emerging. One of these is the clonal origin of metastases ([@B13]), punctuated rather than gradual progression ([@B6]) and the non-linear relationship of on-site and distant metastases, meaning that metastases might be generated from less advanced local tumor foci ([@B13]). Accordingly, it is not completely understood as to which foci in the advanced stage of the disease will progress to CRPC. We followed the idea that the physiological adaptation of the gland to the hypoandrogenic castration-induced environment involves regulatory pathways to maintain the gland in a regressed, low proliferative and less functional (meaning less differentiated) state, and that these pathways in cancer cells might be corrupted and thereby contribute to the progression to CRPC. In this scenario, molecules with enhanced expression after castration might be found to be "tumor suppressors", particularly if they function as hubs in regulatory networks that are defective in cancer cells. *Smad4*, *Ikbkb*, *Rara*, *ets1*, *Bhlhe41*, *Id2*, *Tnfrsf1a*, *Mxi1* and *Dbp* are new candidates, together with the well-known tumor suppressor *Pten*. As a matter of fact, these genes (except ID2 and Mxi1) were found deleted in prostate adenocarcinomas and advanced metastatic prostate cancers.

This also raises the question of whether *Pten*-defective tumors should be submitted to androgen deprivation or blockade, as a major aspect of the prostate response to falling androgen levels relies on this phosphatase.

The functional characterization of the 60 genes revealed interesting attributes. DAVID retrieved 17 pathways, most of them centered on either *Mapk1* or *Mapk9*, which is perhaps too general to indicate new physiological functions. It is worth noticing that MAPK pathway has been implicated in increased survival of castrate-resistant prostate cancer patients ([@B26]).

Next, we uncovered circadian rhythms as a relevant pathway, centered on the genes *Arntl* and *Bhlhe41*. These genes were included in network number 2 retrieved by IPA, which also included the *Dbp* gene, also implicated in circadian regulation. *Arntl* is directly linked to *Dbp* and indirectly to *Ar* via the p300 and CREBBP acetyl transferases. *Dbp* has been reported to have peak expression at 8 h within the light portion of the 12h:12h light/dark cycle (Zeitegeber, ZT 8) in the rat prostate gland ([@B30], [@B37]) in a similar fashion to other core clock genes in the mouse prostate ([@B8]). Moreover, *ARNTL* polymorphisms have been significantly associated with susceptibility to prostate cancer ([@B42])^.^ This evidence raises the possibility that AR-dependent and AR-independent circadian functions contribute to the prostate gland physiology, by opening a new connection to environmental factors, knowingly significant in prostate cancer risk and incidence.

The peroxisome biogenesis pathway, represented by the sole gene Pex14, is also another connection to the environment, as peroxisome proliferation and activity are related to several environmental (and dietary) factors, adding further complexity to the peculiar metabolic adaptations of the gland given its function in accumulating citrate in secretions ([@B36]).

We also found that some of the genes identified in the present investigation map to regions commonly deleted in prostate cancer. In particular, we refer to the *Pten/Hhex/Mxi1* cluster at 10q23, which was characterized in detail before ([@B14]). It will be interesting to investigate whether the differently sized deletions in this region might affect the behavior of prostate cancer cells, as *MXI1* is usually lacking or inactive in prostate cancer ([@B11], [@B29]); its function is to suppress proliferation by antagonizing *Myc* ([@B38]), which in turn is commonly amplified in prostate cancer ([@B19]). It is important to mention that *Mxi1* expression is suggested to decay after castration, according to the parent study ([@B10]). In contrast, *Hhex* expression is increased, which functions as a coordinator of hematopoiesis and the development of endoderm-derived organs such as the liver and thyroid ([@B24]).

Additionaly, we found the *Mapk1* gene, whose homolog *MAPK1* maps to 22q11.21, in a region between the 22q11.21 and 22q12.1 segments deleted in 29% and 33% of intermediate risk tumors, respectively, but not frequently observed in high risk cancers ([@B19]). The *MAPK1* gene product is better known as ERK-2 (or p42 MAPK) and funnels down a variety of extracellular signals to control several functions, particularly the G1-S transition within the cell cycle ([@B25]). The importance of MAPK1 is highlighted by the fact that it was enlisted as a node in 14 of the 17 pathways identified by DAVID, including prostate cancer among others, and the recent demonstration of the existence of identified mutations in members of the MAPK signaling pathway in the serum of 96% tested individuals harboring different tumors ([@B9]). Given the particular association of deletions in this region and the intermediate but not high risk of cancer, MAPK1 might be a protooncogene contributing to PCa progression, metastasis and/or transition to CRPC, and its deletion might represent a lower risk of disease progression.

Finally, we found 20 genes mutated in at least 5% of patients. In contrast to PTEN, mutations in these genes are secondary. However, it has been noted that prostate cancer is commonly associated with diverse low frequency mutations ([@B5]). Nonetheless, six of the identified genes (PHOX2a, NFYC, EST2, EIF251, SSRP1 and PARP1) were found associated with significant impact on patient survival.

The present analysis cannot distinguish between epithelial and stromal contributions to gene expression. Therefore, it is possible that some of the genes studied are expressed in the stroma. As a matter of fact, a previous approach from our laboratory has identified stromal and epithelial subsets of transcription factors ([@B27]).

In conclusion, this work provides insights into the vastness of physiological pathways involving multiple regulatory interactions among genes needed to adjust prostate biology to the reduced androgen levels achieved by surgical or chemical castration. These results are expected to help us understand the idiosyncrasies of prostate cancer.
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